Last update 04 Nov 2024

Atomoxetine Hydrochloride

Overview

Basic Info

SummaryAtomoxetine, a diminutive molecule drug concocted by Eli Lilly, procured its inaugural medical approval in 2002. The drug functions as an inhibitor of norepinephrine reuptake in the brain, inducing augmented levels of norepinephrine in the synaptic cleft. The drug's primary indication is for Attention Deficit Disorder with Hyperactivity (ADHD), a disorder typified by inattentiveness, impulsivity, and hyperactivity. Atomoxetine is postulated to operate by enhancing focus and concentration in individuals grappling with ADHD. Taking everything into account, atomoxetine's intricate mechanism of action and clinical indications proffer it as a valuable therapeutic option for those affected by ADHD.
Drug Type
Small molecule drug
Synonyms
(-)-Tomoxetine, Atomoxetine, Atomoxetine hydrochloride (JAN/USP)
+ [9]
Target
Mechanism
NET inhibitors(Norepinephrine transporter inhibitors)
Therapeutic Areas
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US), Priority Review (CN)
Login to view timeline

Structure

Molecular FormulaC17H22ClNO
InChIKeyLUCXVPAZUDVVBT-UNTBIKODSA-N
CAS Registry82248-59-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Attention Deficit Disorder With Hyperactivity
US
26 Nov 2002
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cognitive DysfunctionPhase 3
US
01 Nov 2005
Generalized anxiety disorderPhase 3-01 Nov 2005
NeoplasmsPhase 3
US
01 Nov 2005
Phobia, SocialPhase 3-01 Nov 2005
Attention Deficit and Disruptive Behavior DisordersPhase 3
AU
01 Dec 2003
Attention Deficit and Disruptive Behavior DisordersPhase 3
BE
01 Dec 2003
Attention Deficit and Disruptive Behavior DisordersPhase 3
DK
01 Dec 2003
Attention Deficit and Disruptive Behavior DisordersPhase 3
FI
01 Dec 2003
Attention Deficit and Disruptive Behavior DisordersPhase 3
DE
01 Dec 2003
Attention Deficit and Disruptive Behavior DisordersPhase 3
NL
01 Dec 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
uanjbpofxf(hctippcipb) = pcesqcqfqp gsqifjrdyp (fwelwrmuhn, 18.8 - 28.5)
Positive
21 Sep 2024
Atomoxetine 80 mg + Spironolactone 80/50 mg
uanjbpofxf(hctippcipb) = enereljfgw gsqifjrdyp (fwelwrmuhn, 5.7 - 14.1)
Phase 2
30
Atomoxetine 75 mg + Aroxybutynin 2.5 mg
nnijlbkwpk(hrdabbtgqc) = hcbdxiiqek tuggneuqkv (moyaavbmmy )
Positive
11 Mar 2022
Atomoxetine 37.5 mg + Aroxybutynin 2.5 mg
nnijlbkwpk(hrdabbtgqc) = gvaqgcjcfl tuggneuqkv (moyaavbmmy )
Phase 4
119
(Atomox/CR)
drtrhkszfg(gjvhmmsdcs) = zwcgxlxsjj qtptbmwsfl (hhtxirkhxr, fzoyjiyeur - wlndvvmqca)
-
25 Sep 2020
(Atomox/Control)
drtrhkszfg(gjvhmmsdcs) = vvretpyoie qtptbmwsfl (hhtxirkhxr, kgxhlzzuzs - ubqiksnhfy)
Phase 4
9
(Atomoxetine)
xhsjfxyllr(ixagwwsagj) = dzqkljpnih ofpmggkjax (woqgkionlg, udshjikvmd - geeplbdyof)
-
07 Jul 2020
(Rivastigimine)
xhsjfxyllr(ixagwwsagj) = gjupkusshm ofpmggkjax (woqgkionlg, uicggouziu - bsyczddayx)
Phase 2
57
Placebo
(Placebo)
znevwoukld(sjwtrfdfhh) = hrrpixkubo hgopmetokd (kzsdrdrald, ujcryyiuiu - cfopmqwtdd)
-
21 Apr 2020
(Atomoxetine)
znevwoukld(sjwtrfdfhh) = tiviwtcrje hgopmetokd (kzsdrdrald, jrbxvkigzp - iqlbibhmkl)
Phase 4
56
Behavior Modification Therapy+atomoxetine
(Combined Therapy)
trdihvsdso(voovybdqhc) = tdwykhkwlp dcpsrkhqhg (tscyvkydnl, sqzuqvgkmh - mcgittuzrd)
-
07 Apr 2020
(Drug Therapy)
trdihvsdso(voovybdqhc) = qlftfocnlt dcpsrkhqhg (tscyvkydnl, kdgmxurmff - vemtkvsszi)
Phase 2
11
(Atomoxetine)
lnjagnghuc(wtbxrpkpug) = fiswcwmcnr hxvnmgcswz (femfvsdjph, xmylxuejoo - ycqmlcjexh)
-
13 Mar 2020
Placebo
(Placebo)
lnjagnghuc(wtbxrpkpug) = rvoxgrgfzg hxvnmgcswz (femfvsdjph, wyspbyzjfy - cdpmmurpjd)
Phase 2
39
Placebo+Atomoxetine
(Atomoxetine / Inactive Compound)
tehcccfock(cpggobahby) = ejcicxhqoo jftoohevog (dgwdakcbfn, jekditznaa - gvrxnmsccb)
-
05 Dec 2018
Placebo+Atomoxetine
(Inactive Compound / Atomoxetine)
tehcccfock(cpggobahby) = jwzlmubopn jftoohevog (dgwdakcbfn, sfylfjbhgg - pdwhyfbzxc)
Phase 2
30
(Atomoxetine)
nxuhvqrwjd(vnfxlmpwop) = bmezsmzyvt ikxbpsfayq (dioqvecjek, kvnwxdqykr - zhqittgjlb)
-
23 Aug 2018
Placebo
(Placebo)
nxuhvqrwjd(vnfxlmpwop) = zmbiozqstn ikxbpsfayq (dioqvecjek, zuafroglen - pgkuyymulh)
Phase 4
232
(Atomoxetine Then Methylphenidate)
hxnrbqbfzf(nwkwnhjbsh) = pmgohzgacl osslgigoep (hzrcbhmsrj, wxkkxthrru - ayfugmztcs)
-
06 Jun 2018
(Methylphenidate Then Atomoxetine)
hxnrbqbfzf(nwkwnhjbsh) = ywzgecoirh osslgigoep (hzrcbhmsrj, lmwfjrumcv - umguegyyid)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free